Targeted adalimumab treatment can optimize long-term outcomes for patients with early RA
Study findings suggest that it may be possible to identify candidates
2011-05-26
(Press-News.org) Results of a study of 1032 patients with early (less than one year), active RA initially assessed response to treatment after 26 weeks with ADA 40mg every other week + MTX versus MTX alone. Results show that 44% of patients treated with the combination therapy achieved the target of sustained low disease activity at week 26, versus 24% of those treated with MTX alone. Patients reaching the target on ADA+MTX were considered responders and then further randomised to continue or withdraw from treatment with ADA 40mg every other week.
Patients who continued treatment maintained good clinical, radiographic and functional responses through to week 78, including a high proportion achieving higher measures of disease control. 77% achieved ACR70*, 86% reached DAS remission (DAS28≤2.6**) and 89% had no radiographic progression***. Interestingly, the majority of patients who had treatment withdrawn also showed good outcomes: 65% and 66% achieved ACR70 response and DAS28≤2.6**, respectively, and 81% showed no radiographic progression. The results in those patients discontinuing ADA indicate that it may be possible to withdraw ADA treatment in specific patients, without impacting long term patient outcomes.
"Data from the OPTIMA study has confirmed previous studies in showing that initial and continued adalimumab treatment in early RA can ensure that higher levels of disease control can be achieved and maintained," said Professor Paul Emery, Leeds Teaching Hospital, Leeds, England, and EULAR President. "Importantly, results of this first global study assessing biologic free disease control demonstrate that it may be possible to successfully withdraw anti-TNF therapy in certain patients and maintain long term positive outcomes although further studies in this area are needed."
Safety findings over the whole study period were generally similar to the profile seen with anti-TNF treatments in the treatment of active RA. Adverse events were evaluated for 850 patients who received ADA: serious adverse events included 9 deaths (1.0 per 100 patient years (/100PY)), 39 serious infections (4.4/100PY); 11 malignancies (1.2/100PY) including 5 non-melanoma skin cancers (0.6/100PY); 8 opportunistic infections (excluding tuberculosis) (0.9/100PY); with 4 confirmed as tuberculosis (0.5/100PY).
INFORMATION:
Abstract Number: THU0251b
*ACR (American College of Rheumatology) criteria measures improvement in tender or swollen joint counts and improvement in three of the following five parameters: acute phase reactant (such as sedimentation rate), patient assessment, physician assessment, pain scale and disability/functional questionnaire. ACR20 refers to a 20% improvement in tender/swollen joint counts, as well as three of the five other criteria. ACR50 refers to a 50% improvement and ACR70 refers to a 70% improvement.
**DAS28 (Disease Activity Score) is an index used by physicians to measure how active an individual's RA is. It assesses number of tender and swollen joints (out of a total of 28), the erythrocyte sedimentation rate (ESR, a blood marker of inflammation), and the patient's 'global assessment of global health'. A higher score indicates more active disease. DAS28≤2.6 has been defined as an indicator of remission
*** Increase of ≤0.5 in total sharp score (TSS), a radiographic damage scoring system, during treatment
NOTES TO EDITORS:
For further information on this study, or to request an interview with the study lead, please do not hesitate to contact the EULAR congress Press Office in Room N12 (opposite the exhibition hall) of the Congress Centre during EULAR 2011 or on:
Email: eularpressoffice@uk.cohnwolfe.com
Rory Berrie:
Onsite tel: +44 7901 513 297
Dimple Natali:
Onsite tel: +44 7900 138 904
About EULAR
The European League Against Rheumatism (EULAR) is the organisation which represents the patient, health professional and scientific societies of rheumatology of all the European nations.
In line with The European Union of Medical Specialists (UEMS), EULAR defines rheumatology as including rheumatic diseases of the connective tissue, locomotor and musculoskeletal systems.
The aims of EULAR are to stimulate, promote, and support the research, prevention, treatment and rehabilitation of rheumatic diseases. To this end, EULAR fosters excellence in education and research in the field of rheumatology. It promotes the translation of research advances into daily care and fights for the recognition of the needs of people with rheumatic diseases.
Diseases of the bone and joints such as rheumatoid arthritis and osteoarthritis cause disability in 4-5% of the adult population and are predicted to rise as people live longer.
EULAR 2011 is set to be the biggest rheumatology event in Europe with over 15,000 scientists, physicians, allied health professionals, and related audiences in attendance from over 100 countries. Over the course of the congress, almost 300 oral and more than 1600 poster abstract presentations will be featured, with 300 invited speaker lectures taking place in more than 140 sessions.
To find out more about the activities of EULAR, visit: www.eular.org
END
ELSE PRESS RELEASES FROM THIS DATE:
2011-05-26
The study, involving 257 students, highlights that a higher degree of pain was experienced with the use of gaming devices compared to mobile phones. Pain reported by children using Xbox and Gameboy was statistically higher than pain reported for the iPhone (p=0.036 and p=0.042 respectively). Importantly, the length of time spent on the devices heightened the pain suffered, as the data demonstrated that length of time was independently associated with the pain reported, with the odds of reporting pain increasing by two (95* CI [1.50, 2.89, p END ...
2011-05-26
Most adverse events were mild and no new safety signals were reported, according to study authors.
Results of the 12 month multinational study, conducted with 792 patients also show that 36.6% and 16.2% of patients achieved ACR50 and ACR70 responses respectively in the 10mg BID group, a significant improvement in symptoms compared to placebo, where 31.2%, 12.7% and 3.2% of patients achieved ACR 20, 50 and 70 respectively. Significant improvements in the Disease Activity Score physician index (DAS28***) were also observed in the treatment groups compared to placebo, along ...
2011-05-26
An international team of UK and US astronomers have spotted the most distant explosion, and possibly the most distant object, ever seen in the Universe.
University of Warwick astronomer Dr Andrew Levan was one of the first members of that team to spot the exploding star, known as a Gamma-ray Burst (GRB), which was briefly as bright as several thousand galaxies (more than a million million times the brightness of the sun). This very bright explosion allowed it to be detected at an extreme estimated distance of 13.14 billion light years - putting it 96% of the way to ...
2011-05-26
Northridge dentist, Dr. Farshid Ariz, DMD, and Dr. Shahdad Arami, DDS, are popular with local residents for many reasons. The technologies that are provided to diagnose and treat dental problems constantly evolve, but these dentists make new investments in technology and stay current with the required education to provide safe and precision dental care. The i-CAT and E4D technologies are now used at Northridge Dental Group to provide patients with safer and more comfortable treatments.
Early detection is a key component in diagnosing severe gum diseases like periodontal ...
2011-05-26
STANFORD, Calif. — A widely used combination of two common medications may cause unexpected increases in blood glucose levels, according to a study conducted at the Stanford University School of Medicine, Vanderbilt University and Harvard Medical School. Researchers were surprised at the finding because neither of the two drugs — one, an antidepressant marketed as Paxil, and the other, a cholesterol-lowering medication called Pravachol — has a similar effect alone.
The increase is more pronounced in people who are diabetic, and in whom the control of blood sugar levels ...
2011-05-26
Japan's earthquake, tsunami and nuclear power plant damage have done more than reduce shipments of popular automobiles and car parts to the United States. Damage from the March disaster at Japanese chemical plants that produce raw materials for the electronics components, although modest in itself, has had some of the most severe impacts in history on the global electronics industry. That's the message from one story in a package of status reports on the disaster in the current edition of Chemical & Engineering News (C&EN), ACS' weekly newsmagazine.
In the articles, C&EN ...
2011-05-26
"Sweet wheat" has the potential for joining that summertime delight among vegetables — sweet corn — as a tasty and healthful part of the diet, the scientific team that developed this mutant form of wheat concludes in a new study. The report appears in the ACS' Journal of Agricultural and Food Chemistry.
Just as sweet corn arose as a mutation in field corn — being discovered and grown by Native American tribes with the Iroquois introducing European settlers to it in 1779 — sweet wheat (SW) originated from mutations in field wheat. Toshiki Nakamura, Tomoya Shimbata and ...
2011-05-26
The formation of abnormal strands of protein called amyloid fibrils — associated with two dozen diseases ranging from Alzheimer's to type-2 diabetes — may not be permanent and irreversible as previously thought, scientists are reporting in the Journal of the American Chemical Society. Rather, protein molecules are constantly attaching and detaching from the fibrils, in a recycling process that could be manipulated to yield new treatments for Alzheimer's and other diseases.
In a study that focused on the fibrils associated with Alzheimer's disease (AD), Natàlia Carulla ...
2011-05-26
Temptations to exceed the speed limit are always plentiful, but only reckless drivers give in to such impulses. Likewise, numerous growth factors always abound in our bodies, but only cancerous cells are quickly "tempted" by these chemicals to divide again and again. Healthy cells, in contrast, divide only after being exposed to growth factors for eight continuous hours. What happens during these eight hours in a healthy cell that resists the call to divide? And even more important, what fails to work properly in the cancerous cell during these same hours? Why do cancerous ...
2011-05-26
The lab, though it may seem quiet and insulated, can be as full of background noise as a crowded train station when we're trying to catch the announcements. Our brains can filter out the noise and focus on the message up to a certain point, but turning up the volume on the loudspeakers – improving the signal-to-noise ratio – helps as well.
Separating out the signal from the noise – increasing one while reducing the other – is so basic that much of scientific research could not take place without it. One common method, developed by the physicist Robert Dicke at Princeton ...
LAST 30 PRESS RELEASES:
[Press-News.org] Targeted adalimumab treatment can optimize long-term outcomes for patients with early RA
Study findings suggest that it may be possible to identify candidates
